Aapro M - Search Results

1

Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.

Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aapro M, et al. Oncologist. 2015 Apr;20(4):450-8. doi: 10.1634/theoncologist.2014-0229. Epub 2015 Mar 20. Oncologist. 2015. PMID: 25795636 Free PMC article. Review.

2

Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.

Nabholtz JM, Thuerlimann B, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Aapro MS, Alaki M, Murawsky M, Riva A. Nabholtz JM, et al. Among authors: aapro ms. Oncology (Williston Park). 1997 Aug;11(8 Suppl 8):25-30. Oncology (Williston Park). 1997. PMID: 9364538 Free article. Clinical Trial.

3

Gemcitabine--a safety review.

Aapro MS, Martin C, Hatty S. Aapro MS, et al. Anticancer Drugs. 1998 Mar;9(3):191-201. doi: 10.1097/00001813-199803000-00001. Anticancer Drugs. 1998. PMID: 9625429 Review.

4

Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001.

Aapro MS. Aapro MS. Oncologist. 2001;6(4):376-85. doi: 10.1634/theoncologist.6-4-376. Oncologist. 2001. PMID: 11524557 Free article. Review.

5

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ. Hesketh PJ, et al. Among authors: aapro m. Eur J Cancer. 2003 May;39(8):1074-80. doi: 10.1016/s0959-8049(02)00674-3. Eur J Cancer. 2003. PMID: 12736106

6

Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement.

Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C, Aapro M. Einhorn LH, et al. Among authors: aapro m. Support Care Cancer. 2005 Feb;13(2):112-6. doi: 10.1007/s00520-004-0704-4. Epub 2004 Oct 9. Support Care Cancer. 2005. PMID: 15480812 Review.

7

Granisetron: an update on its clinical use in the management of nausea and vomiting.

Aapro M. Aapro M. Oncologist. 2004;9(6):673-86. doi: 10.1634/theoncologist.9-6-673. Oncologist. 2004. PMID: 15561811 Free article. Review.

8

Never too old? Age should not be a barrier to enrollment in cancer clinical trials.

Aapro MS, Köhne CH, Cohen HJ, Extermann M. Aapro MS, et al. Oncologist. 2005 Mar;10(3):198-204. doi: 10.1634/theoncologist.10-3-198. Oncologist. 2005. PMID: 15793223 Free article. Review.

9

5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?

Aapro M, Blower P. Aapro M, et al. Cancer. 2005 Jul 1;104(1):1-18. doi: 10.1002/cncr.21141. Cancer. 2005. PMID: 15929119 Free article. Review.

10

Optimising antiemetic therapy: what are the problems and how can they be overcome?

Aapro M. Aapro M. Curr Med Res Opin. 2005 Jun;21(6):885-97. doi: 10.1185/030079905X46313. Curr Med Res Opin. 2005. PMID: 15969889 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

544 results

Search Page